Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 5/20 | 0.42 |
| ▸ | TDO2 | P48775 | 5/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434034 | 0.77 | DPP4 (0.44) | DPP4F2SCN4A | |
| SCHEMBL10654262 | 0.76 | IDO1 (0.48) | IDO1TDO2 | |
| SCHEMBL2840417 | 0.73 | IDO1 (0.38) | DPP4IDO1TDO2 | |
| SCHEMBL16618692 | 0.73 | IDO1 (0.38) | DPP4F2IDO1TDO2 | |
| SCHEMBL518806 | 0.73 | IDO1 (0.38) | DPP4F2IDO1TDO2 | |
| SCHEMBL7851156 | 0.73 | TACR1 (0.39) | IDO1TDO2TACR1 | |
| SCHEMBL2061580 | 0.73 | LMNA (0.38) | IDO1TDO2 | |
| SCHEMBL5196720 | 0.73 | IDO1 (0.38) | DPP4F2IDO1TDO2CACNA1C | |
| SCHEMBL7636381 | 0.73 | TSHR (0.44) | DPP4F2IDO1TDO2 | |
| SCHEMBL27835347 | 0.72 | TAAR1 (0.46) | CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105505128-B | Near-infrared light response self-repairing coating and preparation method thereof | 南京工业大学 | 2018-05-08 | — | — | CN | claimed |
| WO-2020192562-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| EP-2760843-A2 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| CN-103068830-A | Arginase inhibitors and therapeutic uses thereof | MARS INC | 2013-04-24 | — | — | CN | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2496579-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1]HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | Universiteit Gent (BE) | 2012-09-12 | — | — | EP | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20030036558-A1 | Substituted phenoxyacetic acids | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. | 2003-02-20 | — | — | US | disclosed |
| EP-1261327-A2 | ADENOSINE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| CN-1364153-A | Substituted phenoxyacetic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2002-08-14 | — | — | CN | disclosed |
| US-20020107406-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | US | disclosed |
| US-6420426-B1 | USED TO TREAT COMPLICATIONS FROM DIABETES MELLITUS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-16 | — | — | US | disclosed |
| EP-1198451-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6362231-B1 | MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0933354-A1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036558-A1 | Substituted phenoxyacetic acids | SLC5A2, GPR119, SLC5A1 | DPP4 26/4885F2 1570/4885IDO1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.